Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04603339
Other study ID # DIFA-2018-009 - ReStOre@Home
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2021
Est. completion date January 1, 2022

Study information

Verified date April 2022
Source University of Dublin, Trinity College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feasibility study of a 12-week multidisciplinary telehealth rehabilitation programme for survivors of upper gastrointestinal (UGI) cancer


Description:

A single arm feasibility study will be conducted to examine the feasibility of delivering the 12-week ReStOre programme (aerobic and resistance physiotherapy led-exercise, 1:1 dietary counselling and group education sessions) via telehealth to a cohort of upper gastrointestinal cancer survivors.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date January 1, 2022
Est. primary completion date October 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - be = three months post oesophagectomy, total gastrectomy - ± neo-adjuvant/adjuvant chemo/chemoradiotherapy with curative intent - adjuvant therapy must be completed - access to home broadband Exclusion Criteria: - Ongoing serious post-operative morbidity - Evidence of active or recurrent disease. In addition those with any serious co-morbidity that would impact on exercise participation will be excluded including those with; - Uncontrolled hypertension (resting systolic blood pressure >180mmHg and/or diastolic >100mmHg) - Recent serious cardiovascular events (within 12 months) including, but not limited to cerebrovascular accident, and myocardial infarction - Unstable cardiac, renal, lung, liver or other severe chronic disease - Uncontrolled atrial fibrillation - Left ventricular function <50%.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Multidisciplinary rehabilitation programme delivered via telehealth
12 week programme of; 1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions

Locations

Country Name City State
Ireland Trinity College Dublin Dublin Leinster

Sponsors (2)

Lead Sponsor Collaborator
University of Dublin, Trinity College Health Research Board, Ireland

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility - Recruitment Feasibility will be determined by recruitment rate, the number of eligible participants who consent to participation. Through study completion approx 1 year
Primary Feasibility - adherence Feasibility will also be determined by adherence to the trial intervention, the number of prescribed intervention sessions completed. From baseline (T0) to immediately after the program intervention (T1)
Primary Feasibility - acceptability of the intervention (1) Feasibility will also be determined by the acceptability of the programme. Acceptability of the telehealth programme will be assessed by the Telehealth Usability Questionnaire (TUQ).
The Telehealth Usability scale is a 5 point likert scale where 1 = completely disagree, and 5 =fully agree, Higher ratings indicate better usability.
Immediately after the program intervention (T1)
Primary Feasibility - acceptability of the intervention (2) Acceptability of the intervention will be further determined by a qualitative approach.Interviews will be carried out with participants post-intervention to gain their perspectives of the impact of the program on physical and mental well-being and the suitability of the programme to delivery via telehealth Duration of the trial i.e. From enrolment of the first participant until completion of the final participants post-intervention assessment (Time period of up to 12 months).
Secondary Change in Cardiorespiratory Fitness from Baseline Cardiorespiratory fitness will be determined by Cardiopulmonary Exercise Test (CPET) Baseline (T0), Immediately after the program intervention (T1)
Secondary Physical Performance Physical Performance will be measured with the Short Physical Performance Battery Baseline (T0), Immediately after the program intervention (T1)
Secondary Hand Grip Strength Hand Grip strength will be measured with hand held dynamometry Baseline (T0), Immediately after the program intervention (T1)
Secondary Physical Activity Physical activity will be measured using the Godin Shepherd Leisure-Time Exercise Questionnaire. A score of 24 indicates the individual is active, 14-23 indicates moderately active, and less than 14 indicates sedentary/ insufficiently active. Baseline (T0), Immediately after the program intervention (T1)
Secondary Weight Weight will be recorded by standard measures and reported in kilograms (kg). Baseline (T0), Immediately after the program intervention (T1)
Secondary Height Height will be recorded by standard measures and reported in meters (m) Baseline (T0), Immediately after the program intervention (T1)
Secondary Body Mass Index Body Mass Index (BMI) will be calculated as weight (kg)/height (meters(m2)) and reported in kilograms/metres squared (kg/m2). Baseline (T0), Immediately after the program intervention (T1)
Secondary Circumferential Measurements Mid-arm circumference and waist circumference will be measured with a flexible tape measure and reported in centimeters (cm) Baseline (T0), Immediately after the program intervention (T1)
Secondary Health Related Quality of Life measured by the European Organisation for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Quality of Life will be determined by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30).
Scores are reported on a linear scale from 0-100. A high score in a functional scale indicates greater function. A high score in a symptom scale indicates greater symptom burden.
Baseline (T0), Immediately after the program intervention (T1)
Secondary Oesophago-gastric cancer specific Health Related Quality of Life will measured by the European Organisation for the Research and Treatment of Cancer Oesophago-gastric Cancer Subscale the EORTC-QLQ-OG25. Oesophagogastric cancer specific quality of life will be determined by the EORTC-QLQ-OG25 subscale.
Scores are reported on a linear scale from 0-100. A high score in a functional scale indicates greater function. A high score in a symptom scale indicates greater symptom burden.
Baseline (T0), Immediately after the program intervention (T1)
Secondary Fatigue Fatigue will be assessed using the Multidimensional Fatigue Inventory (MFI-20) questionnaire. It is scored from 0-20. A cut off score of >or =13 indicates severe fatigue. Baseline (T0), Immediately after the program intervention (T1)
Secondary Bio-sample Collection Serum, Plasma and Whole Blood samples will be collected at each time-point to establish a survivorship Biobank for UGI cancer. These samples will be stored in the biobank for future to be determined studies. Baseline (T0), Immediately after the program intervention (T1)
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2